Johnson & Johnson Inc., acquired medical device maker Micrus Endovascular for $480 million.

Alcon Inc. (owned completely by Novartis AG) announced rival company acquisition LenSX Lasers Inc. in $361.5 million. The company performs ophthalmologic laser surgery.

Celgene Corp. specialist in multiple myelomas drugs, acquired Abraxis BioSciences for $2.9 billion in cash and stock.

Sanofi-Aventis SA acquired closely held, TargeGen specialist in certain forms of leukemia and blood disorders, and agreed to make an upfront payment of $75 million.

HIV specialist Gilead Sciences Inc. acquired US-based CGI Pharmaceuticals Inc.in $120 million.

Sanofi-Aventis closed a deal with Regulus Therapeutics Inc. with a $750 million potential value to develop microRNA based drugs, a new RNA small scraps of genetic material.

According to the deal, Cadence will access a complete product portfolio with products such as Lonsys, a needle-free system, to deliver painkillers following surgery, as well as pain killer Ofirmev.

Biovail Corp. Canada´s top drug maker, announced merger with Valeant Pharmaceuticals International, in a deal that could end up in a $2 billion revenue company.

Astellas Pharma Inc. concluded OSI Pharmaceuticals Inc. acquisition, therefore now they own cancer drug Tarceva (Erlotinib) indicated to treat advanced lung and pancreatic cancer.

Abbott Laboratories Inc. acquired India-based generic Company Pirrmal Healthcare Ltd. in $3.7 billion. The deal is the second most important of the year for the company, last February Abbott bought Solvaly Pharmaceuticals in $6.2 billion.

Abbott Laboratories Inc. announced that the Federal Trade Commission approved, past March, $722M buy out offer for Facet Biotech Corp.

Wyeth said it had pay30 million to buy privately held biotechnology company Thiakis Ltd. The Madison, New Jersey-based company will make additional payments up to $120 million to private investors of Thiakis if its pipeline achieves certain development milestones and clinical objectives
.

Chicago-based Abbott Laboratories announced a total payment of 175 million dollars to purchase the remaining equity to take over California based Ibis Biosciences Inc. a specialized company in medical diagnostic.

King Pharmaceutical Inc said is exploring alternative financing structure for its $1.6 billion proposed acquisition of Alpharma Inc. Early this week, King agreed to acquire Alpharma, ending a takeover battle and expanding King´s presence into the pain market

Swiss drugmaker Roche Holding AG announced that signed a definitive merger agreement to acquire all the outstanding shares of Memory Pharmaceuticals Inc. in an all-cash transaction for some $50 million. Both companies are already in partnered programmes for disorders such as Alzheimer´s disease and schizophrenia.

King Pharmaceuticals’ and Alpharma Inc’s boards signed an agreement in which the Bristol, Tennessee-based company will acquire Bridgewater, New Jersey-based for about $1.6 billion. The amount is the same that Alpharma had rejected as too low last month and ends a takeover fight that began with King’s $1.4 billion offer last August.

UBS AG bankers were behind Eli Lilly & Co striking the $ 6.5 billion-dollar deal to acquire ImClone Systems Inc, while their own research analyst was telling Eli Lilly it was paying too much.

Bristol-Myers Squibb Co. will sell its 17 percent stake in ImClone Systems Inc., the biotechnology company that agreed today to be bought by Eli Lilly & Co. for $6.5 billion. However, Bristol will continue to co-market in the U.S. ImClone´s only product, the blockbuster drug Erbitux